Trials / Terminated
TerminatedNCT04596995
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rozanolixizumab | Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period. |
Timeline
- Start date
- 2021-01-06
- Primary completion
- 2022-12-21
- Completion
- 2022-12-21
- First posted
- 2020-10-22
- Last updated
- 2024-02-05
- Results posted
- 2024-02-05
Locations
27 sites across 14 countries: United States, China, Georgia, Germany, Hungary, Italy, Japan, Moldova, Poland, Russia, Spain, Taiwan, Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04596995. Inclusion in this directory is not an endorsement.